The global anti-obesity drug market was valued at US$ 1,897.5 Mn in 2021 and is forecast to reach a value of US$ 5,392.4 Mn by 2028 at a CAGR of 16.1% between 2022 and 2028. The global anti-obesity drug market is experiencing strong growth owing to the increasing incidence or prevalence of obesity and increasing burden of obesity and related chronic diseases. Moreover, rise in demand for anti-obesity drugs and increase in research and development is expected to boost the growth of the market. However, factors such as potential side effects of anti-obesity drugs and the availability of alternative therapies are expected to hamper the market growth.
Global Anti-Obesity Drug Market: Regional Insights
Based on geography, the global anti-obesity drug market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Among regions, North America is expected to gain highest share in the market during the forecast period due to the increasing burden of obesity and related chronic diseases and increase in demand for anti-obesity drugs in the region. For instance, obesity in the United States is common and is a major health issue associated with numerous diseases, such as cancer, diabetes, and cardiovascular disease. Trust for America’s Health’s (TFAH) 19th annual report on the nation’s obesity, State of Obesity 2022: Better Policies for a Healthier America found that four in ten American adults have obesity, and obesity rates continue to climb nationwide.
Europe is also expected to witness robust growth in the global anti-obesity drug market due to the increasing prevalence of obesity, rising concern of being overweight or obese, and rise in demand for anti-obesity drugs in the region. For instance, according to WHO European Regional Obesity Report 2022, more than 59% of adults and almost one in three children (29% of boys and 27% of girls) are overweight or living with obesity. Overweight and obesity are among the leading causes of death and disability in the European Region, and obesity prevalence for adults in the European Region is higher than in any other WHO region except for the Americas.
Figure 1. Global Anti-Obesity Drug Market Share (%), by Region, 2022
Global Anti-Obesity Drug Market Drivers:
Increasing burden of obesity to augment the market growth
One of the key factors expected to augment the growth of the global anti-obesity drug market over the forecast period is the increasing incidence or prevalence of obesity across the globe. In adults, obesity is defined as having a BMI of 30.0 or more, according to the Centers for Disease Control and Prevention (CDC). Accruing to the World Obesity Atlas 2022, published by the World Obesity Federation, more than one billion people around the world, including one in five women and one in seven men, will be living with obesity by 2030. This in turn is expected to increase demand for anti-obesity drugs, driving the growth of the market.
Risk of chronic diseases to underpin the market growth
Another factor which is driving the growth of the global anti-obesity drug market is the increasing burden of obesity and related chronic diseases. Obesity is a serious public health problem and the condition significantly increase the risk of various chronic diseases, such as cardiovascular disease, certain cancers, type-2 diabetes, coronary heart diseases, and hypertension. According to NCBI, obesity is a significant risk factor for and contributor to increased morbidity and mortality, from cardiovascular disease (CVD) and diabetes, but also from cancer and other chronic diseases, such as liver and kidney disease, osteoarthritis, depression, and sleep apnea.
Global Anti-Obesity Drug Market Opportunities:
Increasing demand for anti-obesity drugs across the world is expected to offer significant growth opportunities for players in the global anti-obesity drug market. For instance, with the increasing burden of obesity and related chronic diseases and increase in consumer awareness, the demand for anti-obesity drugs is also increasing with the rapid pace. In June 2021, the U.S. Food and Drug Administration (USFDA) approved subcutaneous semaglutide for long-term weight management, with higher doses of 1.7 mg and 2.4 mg once weekly. The Semaglutide Treatment Effect in People with Obesity (STEP) trials have shown the efficacy of semaglutide for the treatment of obesity.
Increase in research and development (R&D) is expected to offer significant growth opportunities for players in the global anti-obesity drug market. For instance, in November 2022, Cosmos Health Inc. announced that it has entered the development phase for CCX0722, an innovative product for obesity and weight management, based on the effectiveness of biocompatible 3D spatial fillers, from natural ingredients. The product is being optimized in terms of its physicochemical properties and its effects on gut microflora through a series of in vitro studies and simulations. Administration of CCX0722 is expected to reduce food intake by rising satiety and reducing appetite.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2021: | US$ 1,897.5 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2028 |
| Forecast Period 2022 to 2028 CAGR: | 16.1% | 2028 Value Projection: | US$ 5,392.4 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Anti-Obesity Drug Market Trends:
Research on several potential drug is a recent trend
The increasing burden of obesity is encouraging researchers and market players to research drugs that can be used to treat obesity. Moreover, owing to increasing obese population and increase in demand for anti-obesity drugs across the globe, players in the market are focusing on developing and launching novel anti-obesity drugs in the market. This trend is expected to continue during the forecast period, driving the growth of the market.
Increase in number of approvals is another trend
The global anti-obesity drugs market is growing steadily with a gradual increase in the number of approvals from the U.S. FDA and European Medicines Agency (EMA). For instance, the FDA has approved several drugs for long-term use for weight loss, such as orlistat, liraglutide, naltrexone-bupropion, phentermine-topiramate, and semaglutide. Currently, the market is gradually growing in the developing regions with the gradual approval of drugs.
Global Anti-Obesity Drug Market Restraints:
Side effects of drugs to hinder growth of the market
One of the key factors expected to hamper the growth of the global anti-obesity drug market is the potential side effects of anti-obesity drugs. Medications that speed up the metabolism and suppress the appetite are risky and can lead to high blood pressure, increase in heart rate, and lung and heart problems. Other possible side effects include an increase in blood pressure, constipation, insomnia, and nervousness, among others. However, an ideal anti-obesity medicine would produce sustained weight loss with minimal side effects.
Availability of alternative therapies to hamper the market growth
Another factor which is hampering growth of the global anti-obesity drug market is the availability of alternative therapies. There are many treatments available to treat obesity, ranging from highly effective bariatric surgery, non-invasive body contouring surgery to less effective nutraceuticals. Gastrointestinal bypass surgery is also the most efficacious and long-lasting treatment for obesity. This in turn is expected to hamper the growth of the market.
Figure 2. Global Anti-Obesity Drug Market Share (%), by Mechanism of Action, 2022
Global Anti-Obesity Drug Market Segmentation:
The anti-obesity drug market report is segmented into Mechanism of Action, Prescription/Non- prescription, and Geography.
Based on Mechanism of Action, the market is segmented into Peripherally Acting Anti-obesity Drugs and Centrally Acting Anti-obesity Drugs. Out of which, Peripherally Acting Anti-obesity Drugs Segment is expected to dominate the anti-obesity drug market over the forecast period and this is attributed to the increase in adoption of peripherally acting anti-obesity drugs. These drugs aid in weight loss, without affecting the brain or suppressing the appetite.
Based on Prescription/Non- prescription, the market is segmented into Prescription Drugs and OTC Drugs. Out of which, Prescription Drugs Segment is expected to dominate the market over the forecast period and this is attributed to the rise in prevalence of obesity worldwide. Prescription drugs as most of the drugs sold in the market are prescription-based drugs, owing to concerns about safety and adverse effects.
Global Anti-Obesity Drug Market: Key Developments
In November 2022, Novo Nordisk planned to boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year (2021).
In October 2022, the U.S. FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Mounjaro is the first weight loss drug to show efficacy rates comparable to surgical procedures like sleeve gastrectomies.
In June 2021, the US Food and Drug Administration (FDA) approved a 2.4 mg/week subcutaneous dose of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy, developed by Novo Nordisk) for weight loss (obesity).
Global Anti-Obesity Drug Market: Key Companies Insights
The global anti-obesity drug market is highly competitive. This is attributed to the rise in demand for safe and effective anti-obesity drugs worldwide, as a result, players in the market are focusing on launching novel products in the market.
Some of the key players in the global anti-obesity drug market are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others.
*Definition: Obesity is commonly defined as having too much body mass. Body mass index (BMI) of 30 or higher is the usual benchmark for obesity in adults. Anti-obesity drugs are commonly used for the treatment of obesity. The U.S. FDA and European Medicines Agency (EMA) has approved several anti-obesity drugs for the treatment of obesity.
Obesity is commonly defined as having too much body mass. Body mass index (BMI) of 30 or higher is the usual benchmark for obesity in adults. Anti-obesity drugs are commonly used for the treatment of obesity. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) has approved several anti-obesity drugs to treat obesity.
Market Dynamics:
Increasing obese population and related chronic diseases, increase in concern of being overweight or obese, increase in demand for anti-obesity drugs, increase in research and development, and the outbreak of COVID-19 are major factors expected to drive growth of the global anti-obesity drug market during the forecast period. For instance, in June 2021, the U.S. FDA approved Semaglutide 2.4 mg for chronic weight management in adults with obesity and/or overweight with at least one weight-related condition (such as high blood pressure or cholesterol, or T2D) for use in addition to a reduced-calorie diet and increased physical activity
Moreover, in January 2021, Novartis announced the results of its Phase II trial of investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline.
Key features of the study:
Detailed Segmentation:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients